How to choose a pharmaceutical exporter from India to the UAE.

The United Arab Emirates is one of the most demanding pharmaceutical markets an Indian exporter can serve, and one of the most rewarding. It imports the large majority of its medicines, it runs a federal registration regime layered with emirate-level health authorities, and it expects hot-climate stability, Arabic labelling and national serialisation before a product reaches a shelf. For a buyer, that means the exporter you choose is not a catalogue vendor. The exporter is the part of your supply chain that either clears MOHAP, the artwork desk and Jebel Ali cleanly, or does not. This is how to tell the two apart.

Why the choice matters more in the UAE.

Most markets forgive a weak supplier slowly. The UAE does not. Three features of the market raise the cost of choosing the wrong Indian exporter.

First, it is import-dependent and regulator-dense. The Ministry of Health and Prevention (MOHAP) registers products and approves prices at the federal level, while the Dubai Health Authority and the Department of Health Abu Dhabi govern facilities and procurement in their emirates. A product has to be registered, priced and compliant before any of those buyers can purchase it, and the exporter supplies the evidence that makes registration possible.

Second, the climate is unforgiving. The UAE sits in ICH Zone IVb, the hot and humid stability zone tested at thirty degrees and seventy-five percent relative humidity. A line whose stability data was generated for a temperate market does not transfer, and a cold-chain product that loses its temperature window between Mumbai and a Dubai warehouse in July is a write-off, not a delay.

Third, the country has moved to national track-and-trace. Tatmeen, the UAE serialisation and traceability system, expects serialised, aggregated packs with the data uploaded before distribution. An exporter who cannot serialise at source cannot supply compliantly, regardless of price.

Put together, these mean the buyer is really evaluating five capabilities, not one price. The rest of this guide takes them in order.

Credential one: WHO-GMP and the quality lattice.

Quality is the gate everything else passes through, so demand the evidence first. The baseline is a current WHO-GMP certificate that is specific to the manufacturing site and the dosage form, not a generic company claim. Behind it sit the Indian CDSCO manufacturing licence (Form 25 or 28), the Certificate of Pharmaceutical Product, and full site identification. A serious exporter puts these on the table at first contact; a weak one offers a product list and promises documents later.

For higher-value and specialist lines, the UAE increasingly rewards a second layer. A manufacturer whose site has been inspected by a stringent regulatory authority, EU-GMP, US FDA, the MHRA or equivalent, or that holds WHO prequalification on the specific molecule, scores materially better on hospital tenders and specialist registrations. WHO-GMP alone is sufficient for many generic lines; the overlay is what separates a commodity supplier from a partner who can carry an oncology or biological line into a tertiary hospital.

M Care's position here is simple: we source only from WHO-GMP sites, we work with EU-GMP-capable partner manufacturers where the line warrants it, and we lead with the certificates rather than the catalogue. The buyer who asks us for site-specific GMP evidence gets it before the conversation moves to price.

Credential two: regulatory command of MOHAP.

The single biggest differentiator between Indian exporters serving the UAE is whether they actually understand the registration regime or merely ship against someone else's. Registration is federal: the product is registered with MOHAP under the name of a UAE-licensed local agent, with a price approved against MOHAP's external reference-pricing basket. The dossier is a full ICH CTD, the Certificate of Pharmaceutical Product is mandatory, and the calendar for a clean new-product file commonly runs nine to eighteen months before commercial supply, pricing included.

There is also a faster lane for products that fit it. The GCC centralised registration pathway lets a single dossier seek approval across Saudi Arabia, the UAE, Kuwait, Oman, Qatar and Bahrain, shortening the multi-state calendar. Knowing when a product belongs in the GCC route versus a direct MOHAP filing is exactly the judgement a buyer should expect their exporter to bring.

The test to apply: ask a prospective exporter to walk you through the MOHAP file for one of your intended molecules, the documents, the sequence, the pricing step and the realistic timeline. A capable partner answers in specifics. M Care prepares the CTD to MOHAP expectations, advises on the MOHAP and wider Gulf registration route per molecule, and drives the file alongside the importer rather than leaving registration as the buyer's problem.

Credential three: documentation and Arabic artwork.

Registration lives or dies on documentation, and the place first shipments most often stall is artwork. UAE labelling expects bilingual Arabic-English on the outer carton, the immediate container where physically possible, and the patient information leaflet, with the brand-name transliteration matching the registration exactly. Arabic added as an afterthought to an English-origin artwork file breaks the right-to-left layout and triggers a rejection cycle that can cost months.

The capable exporter prepares dual-language master artwork from the start, holds the CTD and eCTD dossier ready in the format MOHAP reviewers accept, and presents the approved artwork at registration stage rather than promising it on approval. The buyer should ask to see a sample bilingual carton and a dossier index before committing; the absence of either is a reliable predictor of a slow first shipment.

This is mechanical, unglamorous work, and it is precisely where depth shows. M Care assembles the full CTD, prepares bilingual Arabic-English artwork to MOHAP convention, and keeps the Certificate of Pharmaceutical Product, GMP certificates and stability summaries packaged ahead of submission, not chased after a deficiency letter.

Credential four: cold-chain into a hot market.

The Mumbai-to-UAE lane is short, which is an advantage only if it is handled correctly. Sea freight from Nhava Sheva or Mundra to Jebel Ali, the largest container port in the Middle East, runs roughly five to seven days; air freight through Dubai is a matter of hours. The risk is not distance, it is temperature. Apron heat, tarmac waits and warehouse gaps in a Gulf summer will breach a cold-chain window faster than a long ocean leg in a temperate climate.

What a buyer should require: ICH Zone IVb stability data on every line, validated cold-chain packaging with active or passive shippers chosen against real apron conditions, dual temperature loggers, and a documented chain from the Indian cold-room to the load port. For ambient products, stability referenced to Zone IVb rather than Zone II is the non-negotiable. An exporter who cannot show Zone IVb data is telling you, indirectly, that they built for a different market.

M Care runs validated cold-chain on temperature-sensitive lines, audits the first leg from the Mumbai cold-room to the load port, and routes oncology and biological consignments on active or passive shippers sized to the Gulf summer rather than the brochure.

Credential five: the local-agent structure.

UAE pharmaceutical supply is not a direct-to-hospital business, and an exporter who implies otherwise does not understand the market. Product moves through a UAE-licensed importer or distributor that holds the relevant MOHAP and emirate-level permissions and is the registration holder of record. The Indian exporter supplies and documents to that licensed entity, which sells on to the hospital networks, the Dubai Health Authority and Department of Health Abu Dhabi systems, and the pharmacy chains.

The buyer's interest here is honesty and fit. A strong exporter works cleanly through your importer of record, structures documentation and payment terms around that relationship, and does not pretend to a direct route that does not exist. M Care supplies and documents to the UAE importer of record, builds the commercial paperwork around EUR or USD letters of credit and the importer's licence, and treats the importer relationship as the spine of the lane rather than an obstacle to route around.

Red flags: what to walk away from.

Five signals that an Indian exporter is not built for the UAE, regardless of how attractive the price sheet looks:

• A catalogue instead of certificates. An exporter who leads with a product count and a country count but cannot produce site-specific WHO-GMP evidence on request is selling reach, not capability.
• No Arabic artwork capability. If bilingual artwork is something they will arrange after award rather than show at registration stage, expect the first shipment to slip by months.
• Zone II stability only. Stability data tested at twenty-five degrees and sixty percent humidity, without a Zone IVb bridge, means the portfolio was built for a temperate market and not the Gulf.
• Registration framed as your problem. An exporter who hands over a folder and expects the importer to drive MOHAP alone has not done this before.
• No named, accountable contact. If enquiries disappear into a generic inbox with no person attached and no honest timeline, the supply relationship will behave the same way.

The ten-point buyer's checklist.

Before signing with any Indian pharmaceutical exporter for the UAE, confirm each of these in writing:

1. Current WHO-GMP certificate, specific to the site and dosage form, shown not just claimed.
2. CDSCO manufacturing licence and Certificate of Pharmaceutical Product for every line.
3. EU-GMP, US FDA or MHRA inspection, or WHO prequalification, on the lines that warrant it.
4. A full CTD or eCTD dossier prepared to MOHAP expectations, with an index you can review.
5. Bilingual Arabic-English master artwork prepared in-house, ready at registration stage.
6. ICH Zone IVb stability data on every product, ambient and cold-chain alike.
7. Tatmeen serialisation readiness, with serialised and aggregated packs at source.
8. Validated cold-chain with reefer or qualified passive shippers and dual data loggers.
9. Demonstrated experience driving MOHAP registration alongside a UAE local agent, not leaving it to you.
10. A named person who replies within one working day, with candid timelines rather than promises.

M Care Exports is built to clear all ten. We have shipped Indian WHO-GMP medicines since 2002, we run the UAE as one of our core markets from a Dubai commercial desk, and the credentials above are the standard we hold ourselves to rather than the bar we hope a buyer will not check. The honest summary: the UAE rewards the exporter who treats registration, artwork, stability and cold-chain as the product, and price as the consequence.

FAQ

What credentials should a UAE buyer require from an Indian pharmaceutical exporter?

Ask for the evidence, not the claim. The non-negotiables are a current WHO-GMP certificate specific to the site and dosage form, the Indian CDSCO manufacturing licence and Certificate of Pharmaceutical Product for each line, ICH Zone IVb stability data for the UAE climate, bilingual Arabic-English artwork capability, and Tatmeen serialisation readiness. Stronger suppliers also offer EU-GMP-inspected partner sites for the lines that warrant it. An exporter who answers with a catalogue rather than certificates is not ready for the UAE.

Does the Indian exporter handle MOHAP registration, or does the UAE importer?

Both have a role, and the split is the test of a serious exporter. The product is registered with MOHAP under the name of a UAE-licensed local agent or importer, who is the legal registration holder. But the dossier, the Certificate of Pharmaceutical Product, the GMP evidence, the stability data and the approved artwork all originate from the exporter. A capable exporter prepares the CTD to MOHAP expectations and drives the file alongside the importer rather than handing over a folder and waiting.

Can an Indian company sell pharmaceuticals directly to a UAE hospital?

Not directly. UAE pharmaceutical supply runs through a locally licensed importer or distributor that holds the relevant MOHAP and emirate-level authority permissions, and the product must carry a MOHAP registration. The Indian exporter supplies and documents to that licensed entity, which sells on to hospitals, the Dubai Health Authority and Department of Health Abu Dhabi networks, and pharmacy chains. M Care works through the UAE importer of record rather than implying a direct-to-hospital route that does not exist.

How long does it take to register and start supplying a product in the UAE?

For a new product with a clean dossier, MOHAP registration commonly runs roughly nine to eighteen months, plus pricing approval, before commercial supply can begin. The GCC centralised registration route can shorten the calendar across the six Gulf states for products that fit it. Bilingual Arabic artwork approval and Zone IVb stability are the two steps most often underestimated; preparing both at the start rather than after submission is what keeps the timeline at the lower end.

Is WHO-GMP enough on its own to supply the UAE?

WHO-GMP is the baseline and is mandatory, but for higher-value and specialist lines UAE buyers increasingly prefer manufacturers that also carry inspection by a stringent regulatory authority such as EU-GMP, US FDA or MHRA, or WHO prequalification on the specific molecule. WHO-GMP alone is sufficient for many generic lines; for tenders and specialist products an EU-GMP-inspected partner site materially strengthens the position. M Care sources WHO-GMP throughout and works with EU-GMP-capable partners where the line warrants it.